Pharmaceutical Department has recommended to the Department of Revenue a number of measures including hiking the benefit of weighted exemption to companies engaged in research and development with a view to scale up their overall spending in research activities in the country.

The domestic pharmaceutical market is expected to triple to $20 billion by 2015 from the current $7 billion and move into the world’s top 10 markets.

x (NYSE: LLY) announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.

The cost advantage is luring many pharma companies to prefer India as the destination for contract research and clinical trials to the developed markets, according to a study.